Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]
Truist Financial reiterated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a research report released on Monday, Benzinga reports. Truist Financial currently has a $23.00 price objective on the stock. A number of other research analysts have also recently issued reports on ROIV. TheStreet raised shares of Roivant Sciences from […]
Wolfe Research started coverage on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a research note published on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $17.00 price target on the stock. A number of other equities analysts have also recently commented on ROIV. Deutsche Bank Aktiengesellschaft started coverage on shares […]
Silverarc Capital Management LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company’s stock, valued at approximately $1,168,000. A number of other institutional investors have also recently […]
Roivant Sciences (NASDAQ:ROIV – Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $18.00 to $17.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 54.26% from the company’s […]